Europeans to get alli over the counter
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlineplans to launch alli (orlistat 60mg, licensed from Roche) as an over-the-counter obesity treatment in all 27 EU member states in coming months following European Commissionapproval to switch its prescription status through a centralised procedure. Roche markets a higher-dose, prescription-only orlistat product, Xenical.